|
Summary of significant accounting policies (Tables)
|
12 Months Ended |
|
Jul. 31, 2012
|
| Schedule Of Segment Revenue And Revenue Percentage [Table Text Block] |
The following tables of the Clinical Lab segment’s net
revenues and revenue percentages by revenue category:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2012
|
|
Years ended July
31,
2011
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
category
|
|
|
|
|
(in %)
|
|
|
|
|
(in %)
|
|
|
|
|
(in %)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medicare
|
|
$
|
12,658
|
|
|
21
|
|
$
|
11,856
|
|
|
22
|
|
$
|
11,158
|
|
|
25
|
|
|
Third-party payers
|
|
|
29,616
|
|
|
50
|
|
|
24,335
|
|
|
46
|
|
|
19,534
|
|
|
44
|
|
|
Patient self-pay
|
|
|
11,895
|
|
|
20
|
|
|
11,554
|
|
|
22
|
|
|
8,758
|
|
|
20
|
|
|
HMO’s
|
|
|
5,234
|
|
|
9
|
|
|
5,017
|
|
|
10
|
|
|
4,728
|
|
|
11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
59,403
|
|
|
100
|
%
|
$
|
52,762
|
|
|
100
|
%
|
$
|
44,178
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule Of Accounts Receivable By Segment [Table Text Block] |
The following is a table of the Company’s net accounts
receivable by segment.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
July 31, 2012
|
|
July 31, 2011
|
|
|
|
|
|
|
|
|
Net accounts receivable
by segment
|
|
|
|
|
(in %)
|
|
|
|
|
(in %)
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical Labs (by billing
category)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medicare
|
|
$
|
1,270
|
|
|
16
|
|
$
|
1,434
|
|
|
19
|
|
|
Third party payers
|
|
|
3,478
|
|
|
45
|
|
|
3,087
|
|
|
40
|
|
|
Patient self-pay
|
|
|
2,655
|
|
|
35
|
|
|
2,865
|
|
|
37
|
|
|
HMO’s
|
|
|
330
|
|
|
4
|
|
|
314
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Clinical Labs
|
|
|
7,733
|
|
|
100
|
%
|
|
7,700
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Life Sciences
|
|
|
6,402
|
|
|
|
|
|
7,545
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total accounts
receivable
|
|
$
|
14,135
|
|
|
|
|
$
|
15,245
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in the Company’s allowance for doubtful accounts
are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
July 31, 2012
|
|
July 31, 2011
|
|
|
|
|
|
|
|
|
|
Beginning balance
|
|
$
|
3,488
|
|
$
|
2,839
|
|
|
Provision for doubtful
accounts
|
|
|
5,104
|
|
|
4,431
|
|
|
Write-offs
|
|
|
(5,319
|
)
|
|
(3,782
|
)
|
|
|
|
|
|
|
|
|
|
|
Ending balance
|
|
$
|
3,273
|
|
$
|
3,488
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
The following table sets forth the computation of basic and
diluted net loss per share for the years ended July 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2012
|
|
2011
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(39,269
|
)
|
$
|
(12,960
|
)
|
$
|
(22,233
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common
shares outstanding- Basic
|
|
|
38,798
|
|
|
38,357
|
|
|
38,001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add: effect of dilutive
stock options and restricted stock
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common
shares outstanding - Diluted
|
|
|
38,798
|
|
|
38,357
|
|
|
38,001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
$
|
(1.01
|
)
|
$
|
(0.34
|
)
|
$
|
(0.59
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] |
The following table sets forth the amount of expense related to
share-based payment arrangements included in specific line
items in the accompanying statement of operations for the years
ended July 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2012
|
|
2011
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory
services
|
|
$
|
10
|
|
$
|
10
|
|
$
|
12
|
|
|
Research and
development
|
|
|
4
|
|
|
14
|
|
|
14
|
|
|
Selling, general and
administrative
|
|
|
705
|
|
|
1,025
|
|
|
1,144
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
719
|
|
$
|
1,049
|
|
$
|
1,170
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|